Overview

Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours

Status:
Active, not recruiting

Trial end date:
2024-12-30

Target enrollment:

Participant gender:

Summary

This is a phase I/II national, multicentre, multiple cohort, prospective open-label, non-randomised and non-comparative study, to evaluate the safety and activity of metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy for the treatment of advanced solid tumours.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

UNICANCER

Collaborators:

AstraZeneca
National Cancer Institute, France
Pierre Fabre Laboratories

Treatments:

Antibodies, Monoclonal
Durvalumab
Tremelimumab
Vinblastine
Vinorelbine